ReviewNature biomedical engineering2020
The expanding landscape of inflammatory cells affecting cancer therapy.
Review in Nature biomedical engineering, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 50 citations in OpenAlex.
- Macrophages: Targets for next-generation cancer immunotherapy.Cancer cell · 2026Review
- A Myeloid Cell-Targeted Immunostimulant Cocktail (MyTai) Enhances Cancer Immunotherapy.ACS nano · 2025Article
- Disulfidptosis mechanisms and therapeutic implications in cancer metabolic reprogramming and future perspectives.Discover oncology · 2025Review
- Tumor Microenvironment: From Cervical Carcinogenesis to Therapeutic Advancements.Current pharmaceutical biotechnology · 2025Review
- Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy.Molecular cancer · 2024Review
- Macrophage based drug delivery: Key challenges and strategies.Bioactive materials · 2024Review
- Spon1+ inflammatory monocytes promote collagen remodeling and lung cancer metastasis through lipoprotein receptor 8 signaling.JCI insight · 2024Article
- Pharmacological Polarization of Tumor-Associated Macrophages Toward a CXCL9 Antitumor Phenotype.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Machine learning-driven prognostic analysis of cuproptosis and disulfidptosis-related lncRNAs in clear cell renal cell carcinoma: a step towards precision oncology.European journal of medical research · 2024Article
- Exploring and Analyzing the Systemic Delivery Barriers for Nanoparticles.Advanced functional materials · 2024Article
- Mechanistic studies of tumor-associated macrophage immunotherapy.Frontiers in immunology · 2024Review
- A non-lipid nucleic acid delivery vector with dendritic cell tropism and stimulation.Theranostics · 2024Article
- Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.International journal of nanomedicine · 2024Review
- Insights into the Tumor Microenvironment-Components, Functions and Therapeutics.International journal of molecular sciences · 2023Review
- Macrophage states: there's a method in the madness.Trends in immunology · 2023Review
- Review
- Highly Active Myeloid Therapy for Cancer.ACS nano · 2023Article
- Review
- Targeting cGAS/STING signaling-mediated myeloid immune cell dysfunction in TIME.Journal of biomedical science · 2023Review
- Myeloid cells in the era of cancer immunotherapy: Top 3 unanswered questions.Pharmacology & therapeutics · 2023Review
Corrections and comments
- Erratum issued
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Tumour-infiltrating myeloid cells (TIMCs) are critical regulators of cancer growth. The different phenotypes, functions and therapeutic effects of these phagocytes have, however, been difficult to study. With the advent of single-cell-based technologies, a new 'worldview' is emerging: the classification of TIMCs into subtypes that are conserved across patients and across species. As the landscape of TIMCs is beginning to be understood, it opens up questions about the function of each TIMC subtype and its drugability. In this Perspective, we outline the current map of TIMC populations in cancer and their known and presumed functions, and discuss their therapeutic implications and the biological research questions that they give rise to. The answers should be particularly relevant for bioengineers, materials scientists and the chemical and pharmaceutical communities developing the next generation of cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.